RT Journal Article
SR Electronic
T1 Deciphering the state of immune silence in fatal COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20170894
DO 10.1101/2020.08.10.20170894
A1 Bost, Pierre
A1 De Sanctis, Francesco
A1 Canè, Stefania
A1 Ugel, Stefano
A1 Donadello, Katia
A1 Castellucci, Monica
A1 Eyal, David
A1 Fiore, Alessandra
A1 Anselmi, Cristina
A1 Barouni, Roza Maria
A1 Trovato, Rosalinda
A1 Caligola, Simone
A1 Lamolinara, Alessia
A1 Iezzi, Manuela
A1 Facciotti, Federica
A1 Mazzariol, Anna Rita
A1 Gibellini, Davide
A1 De Nardo, Pasquale
A1 Tacconelli, Evelina
A1 Gottin, Leonardo
A1 Polati, Enrico
A1 Schwikowski, Benno
A1 Amit, Ido
A1 Bronte, Vincenzo
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.08.10.20170894.abstract
AB Since the beginning of the SARS-CoV-2 pandemic, COVID-19 has appeared as a unique disease with unconventional tissue and systemic immune features. While COVID-19 severe forms share clinical and laboratory aspects with various pathologies such as hemophagocytic lymphohistiocytosis, sepsis or cytokine release syndrome, their exact nature remains unknown. This is severely impeding the ability to treat patients facing severe stages of the disease. To this aim, we performed an in-depth, single-cell RNA-seq analysis of more than 150.000 immune cells isolated from matched blood samples and broncho-alveolar lavage fluids of COVID-19 patients and healthy controls, and integrated it with clinical, immunological and functional ex vivo data. We unveiled an immune signature of disease severity that correlated with the accumulation of naïve lymphoid cells in the lung and an expansion and activation of myeloid cells in the periphery. Moreover, we demonstrated that myeloid-driven immune suppression is a hallmark of COVID-19 evolution and arginase 1 expression is significantly associated with monocyte immune regulatory features. Noteworthy, we found monocyte and neutro-phil immune suppression loss associated with fatal clinical outcome in severe patients. Additionally, our analysis discovered that the strongest association of the patients clinical outcome and immune phenotype is the lung T cell response. We found that patients with a robust CXCR6+ effector memory T cell response have better outcomes. This result is line with the rs11385942 COVID-19 risk allel, which is in proximity to the CXCR6 gene and suggest effector memory T cell are a primary feature in COVID-19 patients. By systemically quantifying the viral landscape in the lung of severe patients, we indeed identified Herpes-Simplex-Virus 1 (HSV-1) as a potential opportunistic virus in COVID-19 patients. Lastly, we observed an unexpectedly high SARS-CoV-2 viral load in an immuno-compromised patient, allowing us to study the SARS-CoV-2 in-vivo life cycle. The development of myeloid dysfunctions and the impairment of lymphoid arm establish a condition of immune paralysis that supports secondary bacteria and virus infection and can progress to “immune silence” in patients facing death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04438629Funding StatementThis work was supported by Fondazione Cariverona (ENACT Project, Italy) and Fondazione TIM (Italy)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review board of Azienda Ospedaliera Universitaria di Verona Prot. n.17963 (25 March 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all the other data supporting the findings of this study are available within the article and from the corresponding authors upon reasonable request.